Katsunori Tsuji1, Yutaka J Matsuoka2, Eisuke Ochi3,4. 1. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan. ktsuji@ncc.go.jp. 2. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan. 3. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan. ochi@hosei.ac.jp. 4. Faculty of Bioscience and Applied Chemistry, Hosei University, Tokyo, Japan. ochi@hosei.ac.jp.
Abstract
BACKGROUND: To review the settings and outcomes of high-intensity interval training (HIIT) interventions for breast cancer survivors, and to explore the feasibility of prescribing exercise for breast cancer survivors. METHODS: A systematic search of electronic databases was conducted for studies published up to May 31, 2020. Eligibility criteria included randomized controlled trials of HIIT intervention in breast cancer survivors. Studies were grouped by whether the intervention was conducted during or after breast cancer treatment, and intervention methods and outcomes were reviewed within each group. RESULTS: Twenty-six studies were identified, and 13 satisfied the inclusion criteria. Intervention was conducted during treatment in 8 studies, and after treatment in 5. Intervention duration ranged from 3 to 16 weeks, with 2 or 3 sessions per week, for a total of 9 to 36 sessions. All interventions were supervised; 12 were lab-based, and 1 was community-based. One of most promising outcomes was improvement of cardiorespiratory fitness by HIIT. CONCLUSION: This review found that all studies on HIIT for breast cancer survivors investigated lab-based, supervised interventions, but not home-based or unsupervised. HIIT is a time-efficient method for increasing cardiovascular function in breast cancer survivors, but further research is necessary to determine its effects on other outcomes.
BACKGROUND: To review the settings and outcomes of high-intensity interval training (HIIT) interventions for breast cancer survivors, and to explore the feasibility of prescribing exercise for breast cancer survivors. METHODS: A systematic search of electronic databases was conducted for studies published up to May 31, 2020. Eligibility criteria included randomized controlled trials of HIIT intervention in breast cancer survivors. Studies were grouped by whether the intervention was conducted during or after breast cancer treatment, and intervention methods and outcomes were reviewed within each group. RESULTS: Twenty-six studies were identified, and 13 satisfied the inclusion criteria. Intervention was conducted during treatment in 8 studies, and after treatment in 5. Intervention duration ranged from 3 to 16 weeks, with 2 or 3 sessions per week, for a total of 9 to 36 sessions. All interventions were supervised; 12 were lab-based, and 1 was community-based. One of most promising outcomes was improvement of cardiorespiratory fitness by HIIT. CONCLUSION: This review found that all studies on HIIT for breast cancer survivors investigated lab-based, supervised interventions, but not home-based or unsupervised. HIIT is a time-efficient method for increasing cardiovascular function in breast cancer survivors, but further research is necessary to determine its effects on other outcomes.
Entities:
Keywords:
Cancer survivor; Endurance performance; High intensity interval exercise; Home-based exercise
Authors: Anna Michelotti; Marco Invernizzi; Gianluca Lopez; Daniele Lorenzini; Francesco Nesa; Alessandro De Sire; Nicola Fusco Journal: Breast Date: 2018-12-17 Impact factor: 4.380
Authors: Anne McTiernan; Christine M Friedenreich; Peter T Katzmarzyk; Kenneth E Powell; Richard Macko; David Buchner; Linda S Pescatello; Bonny Bloodgood; Bethany Tennant; Alison Vaux-Bjerke; Stephanie M George; Richard P Troiano; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Sara Mijwel; Daniele A Cardinale; Jessica Norrbom; Mark Chapman; Niklas Ivarsson; Yvonne Wengström; Carl Johan Sundberg; Helene Rundqvist Journal: FASEB J Date: 2018-05-11 Impact factor: 5.191
Authors: Matthew P Wallen; Declan Hennessy; Stephen Brown; Luke Evans; Jonathan C Rawstorn; Anna Wong Shee; Adrian Hall Journal: Eur J Cancer Care (Engl) Date: 2020-05-29 Impact factor: 2.520
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18